AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9496386 — intervention group
Group type: EXPERIMENTAL
Intervention: Epirubicin monotherapy every two weeks
Number of subjects: 167
Study 9496386 — intervention group
Group type: COMPARATOR
Intervention: Epirubicin monotherapy every four weeks
Number of subjects: 167
Study 8369939 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose cefuroxime (1.5 g intravenously before operation)
Number of subjects: 1004
Study 8369939 — intervention group
Group type: COMPARATOR
Intervention: Three-dose cefuroxime regimen (1.5 g before and two doses of 0.75 g after operation)
Number of subjects: 1004
Study 3734571 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified method of ulnar variance measurement
Number of subjects: 100
Study 3734571 — intervention group
Group type: COMPARATOR
Intervention: Palmer method (1982)
Number of subjects: 100
Study 30326888 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-invasive diabetes risk prediction model (German Diabetes Risk Score) during routine health check.
Number of subjects: 300
Study 27576777 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasugrel
Number of subjects: 1230
Study 27576777 — intervention group
Group type: COMPARATOR
Intervention: Ticagrelor
Number of subjects: 1230
Study 24114846 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifaith spiritually based intervention (SBI)
Number of subjects: 23
Study 24114846 — intervention group
Group type: COMPARATOR
Intervention: Supportive psychotherapy (SP)
Number of subjects: 23
Study 22493908 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture and Tuina
Number of subjects: 300
Study 22493908 — intervention group
Group type: COMPARATOR
Intervention: Rehabilitation
Number of subjects: 300
Study 20090676 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin (250 mg oral dosing)
Number of subjects: 12
Study 20090676 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin (125 mg intravenous dosing)
Number of subjects: 12
Study 20090676 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (N=12)
Number of subjects: 12
Study 19391320 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical stimulation
Number of subjects: 16
Study 19391320 — intervention group
Group type: COMPARATOR
Intervention: Conventional physiotherapy
Number of subjects: 16
Study 15705053 — intervention group
Group type: EXPERIMENTAL
Intervention: Abtronic
Number of subjects: 0
Study 15705053 — intervention group
Group type: EXPERIMENTAL
Intervention: Feminique
Number of subjects: 0
Study 12800418 — intervention group
Group type: EXPERIMENTAL
Intervention: Jiawei Mojie Tablet (JMT)
Number of subjects: 63
Study 12800418 — intervention group
Group type: COMPARATOR
Intervention: Yueyueshu Granule (Control)
Number of subjects: 63
Study 11249645 — intervention group
Group type: EXPERIMENTAL
Intervention: MFG‐IRAP gene therapy
Number of subjects: 0
Study 11249645 — intervention group
Group type: COMPARATOR
Intervention: Recombinant IRAP studies
Number of subjects: 0
Study 8888384 — intervention group
Group type: EXPERIMENTAL
Intervention: Flesinoxan (up to 2.4 mg per day)
Number of subjects: 20
Study 8888384 — intervention group
Group type: EXPERIMENTAL
Intervention: Flesinoxan (0.6 or 1.2 mg/day)
Number of subjects: 20
Study 8888384 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 8888384 — intervention group
Group type: EXPERIMENTAL
Intervention: Flesinoxan
Number of subjects: 20
Study 1804665 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral prednisolone 40 mg.day-1
Number of subjects: 107
Study 1804665 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled beclomethasone dipropionate 500 micrograms t.d.s.
Number of subjects: 107
Study 1804665 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 107
Study 6358156 — intervention group
Group type: EXPERIMENTAL
Intervention: Irradiation combined with misonidazole (1 gr/m2, total dose 12 gr/m2)
Number of subjects: 100
Study 6358156 — intervention group
Group type: COMPARATOR
Intervention: Irradiation with placebo
Number of subjects: 100
Study 30782867 — intervention group
Group type: EXPERIMENTAL
Intervention: Cell salvage
Number of subjects: 3028
Study 30782867 — intervention group
Group type: COMPARATOR
Intervention: Standard care without salvage
Number of subjects: 3028
Study 29386515 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab 5mg/kg
Number of subjects: 31
Study 29386515 — intervention group
Group type: COMPARATOR
Intervention: IV polyethylene glycol-treated human immunoglobulin (VGIH) 2g/kg
Number of subjects: 31
Study 26952645 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet Cognitive Behavioral Therapy (MumMoodBooster program)
Number of subjects: 43
Study 26952645 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 43
Study 24882775 — intervention group
Group type: EXPERIMENTAL
Intervention: Lecture and practice sessions with standardized patients (SPs)
Number of subjects: 94
Study 24882775 — intervention group
Group type: COMPARATOR
Intervention: Lecture only
Number of subjects: 94
Study 22452807 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous glucose-insulin-potassium (GIK)
Number of subjects: 871
Study 21044434 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX) in combination with other DMARDs (e.g., leflunomide, cyclosporine, azathioprine, sulfasalazine, gold, hydroxychloroquine)
Number of subjects: 0
Study 21044434 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate (MTX) monotherapy
Number of subjects: 0
Study 21044434 — intervention group
Group type: EXPERIMENTAL
Intervention: Early use of biologics
Number of subjects: 0
Study 17406019 — intervention group
Group type: EXPERIMENTAL
Intervention: Information presentation methods designed to ease cognitive burden
Number of subjects: 3
Study 17406019 — intervention group
Group type: COMPARATOR
Intervention: Standard information presentation methods
Number of subjects: 3
Study 15774255 — intervention group
Group type: EXPERIMENTAL
Intervention: Suprapubic Arch sling (SPARC)
Number of subjects: 84
Study 15774255 — intervention group
Group type: COMPARATOR
Intervention: Tension-free Vaginal Tape (TVT)
Number of subjects: 84
Study 11916808 — intervention group
Group type: EXPERIMENTAL
Intervention: S(+)‐ketamine (0.5 mg/kg bolus before incision, followed by 2 microg x kg(‐1) x min(‐1) infusion until 2 h after emergence from anesthesia)
Number of subjects: 30
Study 11916808 — intervention group
Group type: COMPARATOR
Intervention: NaCl (Control group)
Number of subjects: 30
Study 11092992 — intervention group
Group type: EXPERIMENTAL
Intervention: E15NL (vitamin‐E‐coated ‐ Terumo)
Number of subjects: 20
Study 11092992 — intervention group
Group type: COMPARATOR
Intervention: EE15NL (vitamin‐E‐coated ‐ Terumo)
Number of subjects: 20
Study 9104982 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiopulmonary bypass
Number of subjects: 80
Study 9104982 — intervention group
Group type: COMPARATOR
Intervention: No cardiopulmonary bypass (control group)
Number of subjects: 80
Study 1549961 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate, 10 mg/day for 5 days
Number of subjects: 15
Study 3925746 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous isosorbide dinitrate (ISDN)
Number of subjects: 67
Study 3925746 — intervention group
Group type: COMPARATOR
Intervention: Intravenous nitroglycerin (NTG)
Number of subjects: 67
Study 29316157 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 mg
Number of subjects: 46
Study 29316157 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study 26561408 — intervention group
Group type: EXPERIMENTAL
Intervention: Food basket without education
Number of subjects: 145
Study 26561408 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 145
Study 26561408 — intervention group
Group type: EXPERIMENTAL
Intervention: Food basket with education
Number of subjects: 145
Study 26561408 — intervention group
Group type: EXPERIMENTAL
Intervention: Cash transfer with education
Number of subjects: 145
Study 25073063 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group (High SOC)
Number of subjects: 150
Study 25073063 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group (Low SOC)
Number of subjects: 150
Study 25073063 — intervention group
Group type: COMPARATOR
Intervention: Control group (High trait anxiety)
Number of subjects: 150
Study 25073063 — intervention group
Group type: COMPARATOR
Intervention: Control group (Low trait anxiety)
Number of subjects: 150
Study 22572916 — intervention group
Group type: COMPARATOR
Intervention: Single-session intervention (40-minute in-person, literacy-sensitive training)
Number of subjects: 605
Study 22572916 — intervention group
Group type: EXPERIMENTAL
Intervention: Multisession intervention (initial training plus ongoing telephone-based support)
Number of subjects: 605
Study 22572916 — intervention group
Group type: EXPERIMENTAL
Intervention: Multisession intervention
Number of subjects: 605
Study 20683351 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body vibration (WBV) warm-up
Number of subjects: 22
Study 20683351 — intervention group
Group type: COMPARATOR
Intervention: Dry swings (DS)
Number of subjects: 22
Study 20683351 — intervention group
Group type: EXPERIMENTAL
Intervention: WBV with dry swings (WBVDS)
Number of subjects: 22
Study 19050436 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraarterial autologous BMCs with oral antioxidants and L-arginine
Number of subjects: 18
Study 19050436 — intervention group
Group type: COMPARATOR
Intervention: Maximal drug therapy (control group)
Number of subjects: 18
Study 16189765 — intervention group
Group type: EXPERIMENTAL
Intervention: CT colonography
Number of subjects: 100
Study 16189765 — intervention group
Group type: COMPARATOR
Intervention: Conventional colonography
Number of subjects: 100
Study 12934760 — intervention group
Group type: EXPERIMENTAL
Intervention: Walnut oil (3 g/day in 500 mg capsules) for 45 days
Number of subjects: 60
Study 12934760 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 60
Study 10651694 — intervention group
Group type: EXPERIMENTAL
Intervention: Short course therapy (multiple courses of 12 weeks)
Number of subjects: 40
Study 10651694 — intervention group
Group type: COMPARATOR
Intervention: Continuous therapy (1 year)
Number of subjects: 40
Study 10651694 — intervention group
Group type: EXPERIMENTAL
Intervention: Both short course and continuous therapy
Number of subjects: 40
Study 8880657 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral marital therapy (BMT)
Number of subjects: 36
Study 8880657 — intervention group
Group type: COMPARATOR
Intervention: Interactional couples therapy
Number of subjects: 36
Study 8880657 — intervention group
Group type: COMPARATOR
Intervention: Individual counseling alone
Number of subjects: 36
Study 8880657 — intervention group
Group type: EXPERIMENTAL
Intervention: BMT plus individual counseling
Number of subjects: 36
Study 8880657 — intervention group
Group type: COMPARATOR
Intervention: All three treatments (BMT, interactional therapy, individual counseling)
Number of subjects: 36
Study 1668960 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg acyclovir t.d. for 6 months
Number of subjects: 55
Study 1668960 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study 31567839 — intervention group
Group type: EXPERIMENTAL
Intervention: Static Stretching (SS) for 80 seconds
Number of subjects: 45
Study 31567839 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic Stretching (DS) for 80 seconds
Number of subjects: 45
Study 31567839 — intervention group
Group type: COMPARATOR
Intervention: Control (CON) with no stretching
Number of subjects: 45
Study 29976939 — intervention group
Group type: EXPERIMENTAL
Intervention: Morningness group
Number of subjects: 24
Study 29976939 — intervention group
Group type: COMPARATOR
Intervention: Social jetlag influence
Number of subjects: 24
Study 27973619 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin 1000 mg/d
Number of subjects: 55
Study 27973619 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin 500 mg/d
Number of subjects: 55
Study 27973619 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study 25352484 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular therapy after intravenous r‐tPA
Number of subjects: 0
Study 25352484 — intervention group
Group type: COMPARATOR
Intervention: Intravenous r‐tPA alone
Number of subjects: 0
Study 25352484 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular therapy
Number of subjects: 0
Study 22143708 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% articaine with 1:200,000 adrenaline
Number of subjects: 20
Study 22143708 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine with 1:200,000 adrenaline
Number of subjects: 20
Study 20540144 — intervention group
Group type: EXPERIMENTAL
Intervention: White Tea (WT)
Number of subjects: 70
Study 20540144 — intervention group
Group type: EXPERIMENTAL
Intervention: Green Tea (GT)
Number of subjects: 70
Study 20540144 — intervention group
Group type: COMPARATOR
Intervention: Water (Control)
Number of subjects: 70
Study 19099973 — intervention group
Group type: EXPERIMENTAL
Intervention: SCD group (TLR4 expression)
Number of subjects: 75
Study 19099973 — intervention group
Group type: EXPERIMENTAL
Intervention: CHD group (TLR4 expression)
Number of subjects: 75
Study 19099973 — intervention group
Group type: COMPARATOR
Intervention: SCD group (A and R values)
Number of subjects: 75
Study 19099973 — intervention group
Group type: COMPARATOR
Intervention: CHD group (A value)
Number of subjects: 75
Study 19099973 — intervention group
Group type: COMPARATOR
Intervention: CHD group (R value)
Number of subjects: 75
Study 15948986 — intervention group
Group type: EXPERIMENTAL
Intervention: Air flow at 24 degrees C with SLS 0.5%
Number of subjects: 20
Study 15948986 — intervention group
Group type: EXPERIMENTAL
Intervention: Air flow at 43 degrees C with SLS 0.5%
Number of subjects: 20
Study 15948986 — intervention group
Group type: COMPARATOR
Intervention: Sodium lauryl sulphate (SLS) 0.5% alone
Number of subjects: 20
Study 15948986 — intervention group
Group type: COMPARATOR
Intervention: Air flow alone
Number of subjects: 20
Study 12883517 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive laptop program
Number of subjects: 671
Study 10504076 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrastromal corneal ring segments (ICRS, Intacs)
Number of subjects: 25
Study 9065316 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramazoline aerosol (Rhinospray) 0.14 mg
Number of subjects: 19
Study 9065316 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramazoline aerosol (Rhinospray) 0.19 mg
Number of subjects: 19
Study 1683882 — intervention group
Group type: EXPERIMENTAL
Intervention: Noberastine (NOB) 10 mg
Number of subjects: 250
Study 1683882 — intervention group
Group type: EXPERIMENTAL
Intervention: Noberastine (NOB) 20 mg
Number of subjects: 250
Study 1683882 — intervention group
Group type: EXPERIMENTAL
Intervention: Noberastine (NOB) 30 mg
Number of subjects: 250
Study 1683882 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 250
Study 1683882 — intervention group
Group type: EXPERIMENTAL
Intervention: Noberastine (NOB) 10, 20, and 30 mg
Number of subjects: 250
Study 1683882 — intervention group
Group type: EXPERIMENTAL
Intervention: Noberastine (NOB)
Number of subjects: 250
Study 6352386 — intervention group
Group type: EXPERIMENTAL
Intervention: Bismuth subsalicylate
Number of subjects: 32
Study 6352386 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 31077168 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone cognitive behavioural therapy (tCBT)
Number of subjects: 1002
Study 31077168 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1002
Study 29690626 — intervention group
Group type: EXPERIMENTAL
Intervention: CGA-HHQ(-) coffee
Number of subjects: 15
Study 29690626 — intervention group
Group type: COMPARATOR
Intervention: CGA-HHQ(+) coffee
Number of subjects: 15
Study 26372416 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-concentration hypochlorous acid nasal irrigation
Number of subjects: 37
Study 26372416 — intervention group
Group type: COMPARATOR
Intervention: Isotonic normal saline nasal irrigation
Number of subjects: 37
Study 24280382 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower body positive pressure (LBPP) for 15 minutes
Number of subjects: 29
Study 24280382 — intervention group
Group type: COMPARATOR
Intervention: Control (no LBPP)
Number of subjects: 29
Study 22282432 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg intravenous psilocybin
Number of subjects: 10
Study 22282432 — intervention group
Group type: COMPARATOR
Intervention: Intravenous saline (placebo)
Number of subjects: 10
Study 20231394 — intervention group
Group type: EXPERIMENTAL
Intervention: Artemether-lumefantrine (AL)
Number of subjects: 559
Study 20231394 — intervention group
Group type: EXPERIMENTAL
Intervention: Amodiaquine-sulfadoxine-pyrimethamine (AQ-SP)
Number of subjects: 559
Study 20231394 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine (DP)
Number of subjects: 559
Study 16562406 — intervention group
Group type: EXPERIMENTAL
Intervention: Knowledge of healthy pregnancy habits (assessed through true or false statements)
Number of subjects: 254
Study 16562406 — intervention group
Group type: EXPERIMENTAL
Intervention: Median household income
Number of subjects: 254
Study 16562406 — intervention group
Group type: EXPERIMENTAL
Intervention: Knowledge assessment score
Number of subjects: 254
Study 16562406 — intervention group
Group type: EXPERIMENTAL
Intervention: Previous alcohol use by the pregnant woman
Number of subjects: 254
Study 14526453 — intervention group
Group type: EXPERIMENTAL
Intervention: nCPAP therapy
Number of subjects: 745
Study 14526453 — intervention group
Group type: COMPARATOR
Intervention: No nCPAP therapy (untreated group)
Number of subjects: 745
Study 10898689 — intervention group
Group type: EXPERIMENTAL
Intervention: Stavudine 40 mg single dose in subjects with mild renal impairment (CL(CR) 60 to 80)
Number of subjects: 32
Study 10898689 — intervention group
Group type: EXPERIMENTAL
Intervention: Stavudine 40 mg single dose in subjects with moderate renal impairment (CL(CR) 30 to 50)
Number of subjects: 32
Study 10898689 — intervention group
Group type: EXPERIMENTAL
Intervention: Stavudine 40 mg single dose in subjects with severe renal impairment (CL(CR) </=20)
Number of subjects: 32
Study 10898689 — intervention group
Group type: EXPERIMENTAL
Intervention: Stavudine dosage recommendations for renal impairment (for subjects weighing >/=60 kg)
Number of subjects: 32
Study 10898689 — intervention group
Group type: EXPERIMENTAL
Intervention: Stavudine dosage recommendations for renal impairment (for subjects weighing <60 kg)
Number of subjects: 32
Study 10898689 — intervention group
Group type: EXPERIMENTAL
Intervention: Stavudine in subjects requiring hemodialysis (study II)
Number of subjects: 32
Study 8836274 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical lignocaine 40 mg/ml (4 ml, < or = 3 mg/kg)
Number of subjects: 60
Study 8836274 — intervention group
Group type: COMPARATOR
Intervention: Isotonic saline (4 ml)
Number of subjects: 60
Study 1417068 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish-oil supplements over a 4-week period
Number of subjects: 20
Study 1417068 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 6239884 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen (600 mg) + Tetracycline (250 mg) four times daily
Number of subjects: 68
Study 6239884 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen (600 mg) + Placebo four times daily
Number of subjects: 68
Study 6239884 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetracycline (250 mg) + Placebo four times daily
Number of subjects: 68
Study 6239884 — intervention group
Group type: COMPARATOR
Intervention: Placebo + Placebo four times daily
Number of subjects: 68
Study 30664382 — intervention group
Group type: EXPERIMENTAL
Intervention: Dominant leg press training
Number of subjects: 42
Study 30664382 — intervention group
Group type: EXPERIMENTAL
Intervention: Nondominant leg press training
Number of subjects: 42
Study 30664382 — intervention group
Group type: COMPARATOR
Intervention: Nontraining control
Number of subjects: 42
Study 27811012 — intervention group
Group type: EXPERIMENTAL
Intervention: Lapatinib
Number of subjects: 4674
Study 27811012 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 4674
Study 25608747 — intervention group
Group type: COMPARATOR
Intervention: Conventional Stress Echocardiography (CSE)
Number of subjects: 1649
Study 25608747 — intervention group
Group type: EXPERIMENTAL
Intervention: Real Time Myocardial Contrast Echocardiography (RTMCE)
Number of subjects: 1649
Study 23577062 — intervention group
Group type: EXPERIMENTAL
Intervention: Biojector® 2000™ delivery of DNA vaccine (VRC-HIVDNA016-00-VP)
Number of subjects: 40
Study 23577062 — intervention group
Group type: COMPARATOR
Intervention: Needle and syringe (N/S) delivery of DNA vaccine (VRC-HIVDNA016-00-VP)
Number of subjects: 40
Study 21950763 — intervention group
Group type: EXPERIMENTAL
Intervention: LVAD patients 3 months after implantation
Number of subjects: 7
Study 21950763 — intervention group
Group type: COMPARATOR
Intervention: LVAD patients 1 and 3 months after implantation
Number of subjects: 7
Study 19327967 — intervention group
Group type: EXPERIMENTAL
Intervention: Levetiracetam
Number of subjects: 115
Study 16686722 — intervention group
Group type: COMPARATOR
Intervention: Solifenacin (5 mg)
Number of subjects: 1041
Study 16686722 — intervention group
Group type: COMPARATOR
Intervention: Solifenacin (10 mg)
Number of subjects: 1041
Study 16686722 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1041
Study 16686722 — intervention group
Group type: EXPERIMENTAL
Intervention: Open-label solifenacin treatment
Number of subjects: 1041
Study 15467097 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidant supplement
Number of subjects: 18
Study 15467097 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 11344197 — intervention group
Group type: EXPERIMENTAL
Intervention: human corticotropin-releasing hormone (hCRH)
Number of subjects: 8
Study 11344197 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 8
Study 11344197 — intervention group
Group type: EXPERIMENTAL
Intervention: ovine corticotropin-releasing hormone (oCRH)
Number of subjects: 8
Study 9711470 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrendipine 20 mg once daily
Number of subjects: 33
Study 9711470 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide 25 mg once daily
Number of subjects: 33
Study 7974297 — intervention group
Group type: EXPERIMENTAL
Intervention: Nedocromil sodium (4 x 8 mg/day)
Number of subjects: 54
Study 7974297 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54